

RENAL CELL CARCINOMA PRECEPTORSHIP - Chair: Prof. M. Schmidinger

Medizinischen Universität Wien, May 6-7, 2020

May 6		
Time	Title	Contents
09:00-11:00	Hospital visit	A guided tour through the facilities
11:00-11:15	Welcome and introduction	Aim of this meeting
11:15-11:45	RCC background	Renal cancer risk factors; Stages of the disease; Epidemiology; Do “historical” therapies still play a role?
11:45-12:00	Q&A	
12:00-12:45	Deep dive into the pharmacologic properties of RCC treatments	What are the key differences within targeted drugs and immune checkpoint inhibitors
12:45-13:30	Lunch	
13:30-14:00	Surgical RCC therapy	The role of surgical therapy in the localised and metastasised stages, pros and cons as well as indications of different techniques, the importance of biopsy
14:00-14:45	Hot Topics 2020 Part 1	The importance of topical therapy of mRCC, First-line therapy selection
14:45-15:15	Hot Topics 2020 Part 2	Second-line therapy selection, and subsequent therapies
15:15-15:30	Coffee Break	
15:30-16:15	Patient cases (1)	Interactive case-discussion Good and bad therapy decisions, beyond guidelines

16:15-17:00	Patient cases (2)	Interactive case-discussion Good and bad therapy decisions, beyond guidelines
17:00-17:30	Adjuvant/neoadjuvant therapy	Available data, "to do or not to do"
17:30-17:45	Q&A	
17:45	End of Day 1	
May 7		
Time	Title	Contents
09:00-09:45	Therapy management	Mechanism and management of TKI-induced toxicities Management of check-point inhibitor-related toxicities
9:45-10:00	Q&A	
10:00-10:20	Toxicity quiz	Who Wants to Be a Millionaire?
10:20-10:45	Coffee Break	
10:45-11:30	Patient cases (3)	How would you manage this patient?
11:30-12:15	Non-cc-RCC	Is there a Standard of Care for this?
12:15-12:30	Q&A	
12:30-13:15	Lunch	
13:15-13:45	Patient communication	How can therapy adherence and compliance be improved? Challenges when talking with a patient
13:45-14:15	Living with mRCC	A doctor as a patient
14:15-14:30	Q&A	
14:30	End of the Meeting	
	Faculty:	Manuela Schmidinger - Romano Danesi - Ernst Agneter - Mesut Remzi plus a couple of speakers from the Team (still TBD).